In recent years, an increasing number of clinical studies have demonstrated that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can prolong progression-free survival (PFS) and alleviate clinical symptoms of patients with advanced NSCLC harboring EGFR-sensitive mutations [18,19,20]. Here, EGFR is linked to non-small cell lung carcinoma.